NCT02133131View on ClinicalTrials.gov

Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

PHASE2CompletedINTERVENTIONAL

Enrollment

143

Participants

Timeline

Start Date

June 13, 2014

Primary Completion Date

November 2, 2015

Study Completion Date

February 1, 2016

Conditions

Hepatitis C

Interventions

DRUG

Grazoprevir/Elbasvir FDC

FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.

DRUG

Sofosbuvir

Sofosbuvir 400mg tablet taken q.d. by mouth.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02133131 - Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074) | Biotech Hunter | Biotech Hunter